BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 25909227)

  • 21. [Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].
    Yu BH; Zhou XY; Xiao XY; Yan SY; Qin T; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):35-41. PubMed ID: 19489223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
    Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.
    Wu Z; He B; He J; Mao X
    Prostate; 2013 May; 73(6):596-604. PubMed ID: 23060044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-489 inhibits proliferation, cell cycle progression and induces apoptosis of glioma cells via targeting SPIN1-mediated PI3K/AKT pathway.
    Li Y; Ma X; Wang Y; Li G
    Biomed Pharmacother; 2017 Sep; 93():435-443. PubMed ID: 28666210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway.
    Boreddy SR; Pramanik KC; Srivastava SK
    Clin Cancer Res; 2011 Apr; 17(7):1784-95. PubMed ID: 21350002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma.
    Gu L; Song G; Chen L; Nie Z; He B; Pan Y; Xu Y; Li R; Gao T; Cho WC; Wang S
    Acta Haematol; 2013; 130(2):87-94. PubMed ID: 23548551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
    Yao XX; Wang JF; Wang YH; Gao N
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-21 inhibitor suppressed the progression of retinoblastoma via the modulation of PTEN/PI3K/AKT pathway.
    Gui F; Hong Z; You Z; Wu H; Zhang Y
    Cell Biol Int; 2016 Dec; 40(12):1294-1302. PubMed ID: 27600360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway.
    Huang Y; Fan X; Tao R; Song Q; Wang L; Zhang H; Kong H; Huang J
    J Cell Physiol; 2018 Oct; 233(10):6693-6704. PubMed ID: 29323718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EB-virus latent membrane protein 1 potentiates the stemness of nasopharyngeal carcinoma via preferential activation of PI3K/AKT pathway by a positive feedback loop.
    Yang CF; Yang GD; Huang TJ; Li R; Chu QQ; Xu L; Wang MS; Cai MD; Zhong L; Wei HJ; Huang HB; Huang JL; Qian CN; Huang BJ
    Oncogene; 2016 Jun; 35(26):3419-31. PubMed ID: 26568302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway.
    Wang L; Tang B; Han H; Mao D; Chen J; Zeng Y; Xiong M
    Cancer Biother Radiopharm; 2018 Feb; 33(1):32-38. PubMed ID: 29412697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
    Ohta K; Hoshino H; Wang J; Ono S; Iida Y; Hata K; Huang SK; Colquhoun S; Hoon DS
    Oncotarget; 2015 Feb; 6(5):3211-24. PubMed ID: 25633810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
    Ezell SA; Wang S; Bihani T; Lai Z; Grosskurth SE; Tepsuporn S; Davies BR; Huszar D; Byth KF
    Oncotarget; 2016 Feb; 7(8):9163-74. PubMed ID: 26824321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.